Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

(2021) Léna Royston et al.   Vaccines

Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients

(2021) Joshua A. Hill et al.   Blood Advances

Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study

(2020) Phaedon Zavras et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients

(2020) Anthony Anderson et al.   CLINICAL TRANSPLANTATION

Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation

(2020) Jiaqi Fang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant

(2020) Joyce J. Johnsrud et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy and Pharmacoeconomic Impact of Letermovir for CMV Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients

(2019) Shelby Lorraine Merchant et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation

(2019) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy

(2019) Jennifer L. Saullo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation

(2019) Prashant Sharma et al.   BONE MARROW TRANSPLANTATION

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

(2016) P. Teira et al.   BLOOD

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

(2016) Margaret L Green et al.   Lancet Haematology

The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches

(2014) Natasha A. Jain et al.   CYTOTHERAPY

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

(2011) Per Ljungman et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

How we treat cytomegalovirus in hematopoietic cell transplant recipients

(2009) M. Boeckh et al.   BLOOD

Toward the Individualization of Cytomegalovirus Control after Solid‐Organ Transplantation: The Importance of the “Individual Pathogenic Balance”

(2009) Julian Torre‐Cisneros   CLINICAL INFECTIOUS DISEASES

An Assessment of Donor‐to‐Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants

(2009) Oriol Manuel et al.   JOURNAL OF INFECTIOUS DISEASES

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE